Botanical Drugs: The Next New New Thing?

DSpace/Manakin Repository

Botanical Drugs: The Next New New Thing?

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Li, Weishi en_US
dc.date.accessioned 2012-07-06T21:32:23Z
dc.date.issued 2002 en_US
dc.identifier.citation Botanical Drugs: The Next New New Thing? (2002 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965577
dc.description.abstract While herbal medicines hold great promises for treating diseases, they also have serious limitation in their current forms. Currently the regulatory scheme for herbal medicines in the United States is inadequate and it undercuts the incentives for American industry to develop drug products from herbal medicines. This paper argues that FDA should develop a drug model for herbal medicines. This will help both to mainstream herbal medicines in the United States, and to alleviate the production crisis that the American pharmaceutical industry is facing. This paper also assesses FDA~{!/~}s new Draft Guidance for Botanical Drug Products for its incentivizing effects on the industry. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject botanical drug en
dc.title Botanical Drugs: The Next New New Thing? en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-07-06T21:32:23Z

Files in this item

Files Size Format View
Li.pdf 164.1Kb PDF View/Open
Li.rtf 122.6Kb RTF file View/Open
Li.html 107.6Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters